TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39033266
Drug: Food allergen-specific
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food allergen-specific substitutive diet (FASSD) as a 6-month dietary treatment option.
Study: 39033367
Drug: Flushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flushing with 2 ml of clear follicular fluid from 2 to 3 dominant follicles after oocyte retrieval
Study: 39033370
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg triptorelin (Decapeptyl)
Study: 39033370
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of GnRH agonist
Study: 39033369
Drug: DLBS3233 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DLBS3233 100-mg daily
Study: 39033369
Drug: Metformin-XR 750
Normalized name: metFORMIN Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-XR 750 mg twice daily
Study: 39033767
Drug: Lenalidomide 5
Normalized name: lenalidomide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 5 mg daily for 2 years
Study: 39033770
Drug: Pirtobrutinib 200
Normalized name: PIRTOBRUTINIB 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirtobrutinib 200 mg orally once a day in 28-day cycles
Study: 39033770
Drug: Pirtobrutinib 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirtobrutinib 150 mg orally once a day (1 patient)
Study: 39034493
Drug: Lethally irradiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lethally irradiated lymphoma cells admixed with GM-K562 cells; maximum of 6 vaccines administered
Study: 39034968
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus lorlatinib (100 mg once daily)
Study: 39034968
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus crizotinib (250 mg twice daily)
Study: 39035147
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel applied daily internally and externally to the genital area for approximately 6 months (short-term) and optionally up to 2 years (long-term)
Study: 39035685
Drug: Combination acupoints
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination acupoints (Zhongwan, CV-12 and Zusanli, ST-36)
Study: 39036981
Drug: VIR-2482 450
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2482 450 mg
Study: 39036981
Drug: VIR-2482 1200
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIR-2482 1200 mg
Study: 39037543
Drug: HR070803 (liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR070803 (liposomal irinotecan) in combination with 5-fluorouracil and leucovorin, intravenous infusion from 60 to 80 mg/m²
Study: 39038096
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (BMT) plus endovascular treatment (EVT)
Study: 39038268
Drug: Carfilzomib, Lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) followed by high-dose melphalan (200 mg/m2)
Study: 39038282
Drug: Digital health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital health coaching intervention, including asynchronous messages 1-2 times per week, unlimited access to the coach, and monthly videoconference or phone meetings over a 4-month period.
Study: 39038477
Drug: Heterologous HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous HIV-1 vaccine regimen (Ad26.Mos4.HIV and clade C gp140)
Study: 39038477
Drug: Heterologous HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous HIV-1 vaccine regimen
Study: 39038479
Drug: Luspatercept (1·0-1·75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luspatercept (1·0-1·75 mg/kg body weight, subcutaneously, once every 3 weeks)
Study: 39038479
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (450-1050 IU/kg body weight, subcutaneously, once a week; max total dose 80,000 IU)
Study: 39038701
Drug: First-, second-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-, second-, or third-line systemic therapy for chronic GVHD
Study: 39038815
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg at week 0, week 4, and every 12 weeks thereafter through week 52.
Study: 39038990
Drug: Topical menthol
Normalized name: menthol Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical menthol (1% menthol applied to hands and feet, two times a day)
Study: 39039005
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia only (group G)
Study: 39039387
Drug: Spesolimab IV
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab IV (450 mg, 900 mg, 1200 mg)
Study: 39039387
Drug: Spesolimab SC
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab SC (300 mg, 600 mg)
Study: 39039449
Drug: ABTL0812 (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABTL0812 (1300 mg tid) combined with carboplatin (AUC 5) and paclitaxel (175 mg/m2)
Study: 39039449
Drug: ABTL0812 (1300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABTL0812 (1300 mg tid)
Study: 39039488
Drug: TIME case
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIME case conferences structured based on cognitive behavioural therapy (CBT)
Study: 39039509
Drug: Overnight peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight peripheral parenteral nutrition (PPN)
Study: 39039609
Drug: Integrated management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated management strategies including health worker training, adaptation of HIV EHR for HTN/CVD care, and use of treatment partners
Study: 39039666
Drug: Obinutuzumab-based immuno-chemotherapy
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab-based immuno-chemotherapy and maintenance
Study: 39039833
Drug: TFP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFP block (20 ml 0.25% bupivacaine for each side)
Study: 39039833
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block (20 ml 0.25% bupivacaine for each side)
Study: 39040037
Drug: Integrative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative care (IC) model including ACS secondary prevention program and depression care (case screening, group counselling, individual problem-solving therapy)
Study: 39040184
Drug: IVIG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (2 g/kg) alone
Study: 39040184
Drug: IVIG (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (2 g/kg) with high-dose aspirin (80-100 mg/kg/day) until fever subsided for 48 hours, followed by daily aspirin (3-5 mg/kg) for six weeks
Study: 39040670
Drug: Celsior® solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celsior® solution
Study: 39040670
Drug: St Thomas®
Approvals — FDA: no, EMA: no, PMDA: no
Description: St Thomas® solution
Study: 39041411
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 6 months with salvage radiotherapy (SRT)
Study: 39041411
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 24 months with salvage radiotherapy (SRT)
Study: 39041887
Drug: Vaccine (Flublok;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (Flublok; Sanofi Pasteur)
Study: 39041933
Drug: Increased differential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased differential stroke volume (greater than 30 mL)
Study: 39041933
Drug: Balanced differential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced differential stroke volume (greater than or equal to -30 mL to ≤30 mL)
Study: 39041933
Drug: Negative differential
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative differential stroke volume (less than -30 mL)
Study: 39042292
Drug: CT-P41 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P41 (60 mg subcutaneous)
Study: 39042407
Drug: ZY5301 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY5301 300 mg/d
Study: 39042407
Drug: ZY5301 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY5301 600 mg/d
Study: 39042875
Drug: Algorithm designed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Algorithm designed to guide the deprescribing of drugs for OAB
Study: 39043009
Drug: Durvalumab 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 10 mg/kg plus Tremelimumab 3 mg/kg
Study: 39043009
Drug: Durvalumab 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 20 mg/kg plus Tremelimumab 1 mg/kg
Study: 39043009
Drug: Durvalumab 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 20 mg/kg plus Tremelimumab 1 mg/kg (dose expansion cohort)
Study: 39043009
Drug: Durvalumab 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 10 mg/kg plus Tremelimumab 1 mg/kg (dose expansion cohort)
Study: 39043009
Drug: All dose-expansion
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose-expansion cohorts
Study: 39043146
Drug: FYTF-919 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FYTF-919 (100 mL per day, oral)
Study: 39043348
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (ASA, 81 mg/day) during sleep restriction
Study: 39043348
Drug: Low-dose acetylsalicylic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetylsalicylic acid (ASA, 81 mg/day) during recovery sleep
Study: 39043513
Drug: StrataGraft treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: StrataGraft treatment
Study: 39043593
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy plus health education (intervention group, n=20)
Study: 39043650
Drug: 20 min
Normalized name: wheat germ oil 20 minim ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min daily HVBR (fast breathing with long breath holds) for 3 weeks
Study: 39043915
Drug: Milk supplementation
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplementation (390 ml daily)
Study: 39044381
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (10 mg/kg once) with fluconazole
Study: 39044861
Drug: Vaccine adverse
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine adverse effects after dose one
Study: 39045544
Drug: Toripalimab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (240 mg) every 3 weeks plus nab-paclitaxel weekly for 12 weeks after four cycles of epirubicin-cyclophosphamide every 2 weeks
Study: 39045795
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for PTSD
Study: 39602624
Drug: Subcutaneous lenacapavir
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lenacapavir every 26 weeks
Study: 39046157
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral emtricitabine-tenofovir alafenamide (F/TAF)
Study: 39046157
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; active control)
Study: 39046314
Drug: Intra-articular hip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hip injection with prior subcutaneous LA (2 mL of lidocaine 1%)
Study: 39046314
Drug: Intra-articular hip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hip injection without prior subcutaneous LA
Study: 39046314
Drug: Intra-articular hip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hip injection with prior subcutaneous LA
Study: 39046333
Drug: Concomitant inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant inhibitors or inducers of cytochrome P450 3A4 and/or P-glycoprotein
Study: 39046647
Drug: Sanjie Analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanjie Analgesic Capsule (SAC) 1.6 g 3 times per day for 3 menstrual cycles
Study: 39046647
Drug: Placebo 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.6 g 3 times per day for 3 menstrual cycles
Study: 39046695
Drug: LAMA +
Normalized name: Lama palagi oil
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMA + long-acting β agonist
Study: 39046695
Drug: Other inhaler
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other inhaler treatments
Study: 39046695
Drug: Inhaler treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler treatment (general)
Study: 39046741
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention group (pharmacist-led OAC prescription)
Study: 39046767
Drug: Ruxolitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (10 mg twice daily for ages ≥12 to <18 years; 5 mg twice daily for ages ≥6 to <12 years; 4 mg/m2 twice daily for ages ≥2 to <6 years)
Study: 39047219
Drug: Extended letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended letrozole therapy (ELT)
Study: 39047868
Drug: Creatine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (20 g/day for 7 days)
Study: 39048608
Drug: Clesacostat (PF-05221304),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clesacostat (PF-05221304), an acetyl coA carboxylase inhibitor (ACCi), 25 mg dosage.
Study: 39048701
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + Manual Therapy (ETManual therapy)
Study: 39048932
Drug: POINCARE-2 strategy
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: POINCARE-2 strategy (daily weighing and administration of treatments)
Study: 39048933
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise programme in primary care (aerobic and strengthening exercises, twice a week for 12 weeks, daily walks)
Study: 39048933
Drug: Unsupervised home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised home-based exercise (daily walks and sit-to-stand exercise)
Study: 39049019
Drug: Sequential 4-channel
Normalized name: CHANNEL CATFISH
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential 4-channel neuromuscular electrical stimulation (NMES)
Study: 39049042
Drug: Biomarkers investigated
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarkers investigated (neuropsychological tests: MMSE and delayed free recall, brain glucose metabolism)
Study: 39049073
Drug: Orlistat (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (360 mg/day)
Study: 39049087
Drug: Incretin effect
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incretin effect measured as the difference between plasma insulin area under the curve during an oral glucose tolerance test (OGTT) and intravenous glucose infusion.
Study: 39049187
Drug: Water-filtered infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-filtered infrared A radiation (WIRA) whole-body hyperthermia combined with immune checkpoint inhibitor (ICI) therapy (tislelizumab)
Study: 39049618
Drug: Friction mechanics
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friction mechanics using elastomeric chain (160 g/side)
Study: 39049802
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment with saline infusion
Study: 39049802
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment with exendin(9-39)NH2 infusion
Study: 39052242
Drug: Bintrafusp alfa,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa, 1200 mg, intravenously once every 2 weeks
Study: 39052256
Drug: Atezolizumab, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab, 1200 mg intravenously, administered on day 1 of each 21-day cycle for four cycles, followed by chemoradiation therapy (CRT)
Study: 39052256
Drug: Atezolizumab, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab, 1200 mg every 21 days continued for 1 year after CRT
Study: 39052256
Drug: Atezolizumab, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab, 1200 mg, as part of the treatment regimen
Study: 39052256
Drug: Atezolizumab treatment
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab treatment
Study: 39052716
Drug: RSM01, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSM01, an investigational anti-RSV prefusion F monoclonal antibody (mAb); details on dosage and duration not available.
Study: 39052715
Drug: 3-day azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day azithromycin treatment
Study: 39052715
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment (control)
Study: 39052893
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) surgery with audible ECochG monitoring
Study: 39052893
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) surgery without audible ECochG monitoring
Study: 39053295
Drug: Pandemic-adjusted family/systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic-adjusted family/systemic constellation therapy
Study: 39053611
Drug: Deuruxolitinib 8
Normalized name: Deuruxolitinib
DrugBank: Deuruxolitinib (DB18847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuruxolitinib 8 mg twice daily
Study: 39053611
Drug: Deuruxolitinib 12
Normalized name: Deuruxolitinib
DrugBank: Deuruxolitinib (DB18847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deuruxolitinib 12 mg twice daily
Study: 39053878
Drug: Subcrestal ≈2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal ≈2 mm implants with LA
Study: 39053878
Drug: Subcrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal implants
Study: 39053948
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg plus background csDMARD(s)
Study: 39053954
Drug: Allopurinol (200-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (200-500 mg daily)
Study: 39053957
Drug: BETTER Women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: BETTER Women programme with a trained peer health coach providing ongoing support after receipt of a BETTER prevention prescription.
Study: 39053960
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg AMK injection on the first and fourth day of treatment
Study: 39053961
Drug: Early pharmacotherapeutic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early pharmacotherapeutic treatment of clinically symptomatic and echocardiography-confirmed haemodynamically significant PDA
Study: 39054420
Drug: Renin-Angiotensin-System (RAS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-Angiotensin-System (RAS) blockers with beta-blockers and optionally spironolactone
Study: 39054460
Drug: Irreversible Electroporation
Normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irreversible Electroporation (IRE) followed by reduced dose MR guided Radiation Therapy (MRgRT) with either 32.5 Gy in 5 Fractions or 22 Gy in 2 fractions
Study: 39054462
Drug: E + P + C (epacadostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + P + C (epacadostat 100 mg BID + pembrolizumab 200 mg every 21 days + platinum-based chemotherapy)
Study: 39054462
Drug: PBO + P + C (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO + P + C (placebo + pembrolizumab 200 mg every 21 days + platinum-based chemotherapy)
Study: 39054476
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 21 days plus oral epacadostat 100 mg twice daily (combination)
Study: 39054485
Drug: Epacadostat 100
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat 100 mg BID plus pembrolizumab
Study: 39054514
Drug: Exercise combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise combined with Manual Therapy (MT)
Study: 39054770
Drug: (2R,6R)-Hydroxynorketamine (RR-HNK)
Normalized name: Zithranol-RR
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2R,6R)-Hydroxynorketamine (RR-HNK) at doses of 0.1-4 mg/kg (SAD) and 1-2 mg/kg (MAD) administered via IV over 40 minutes
Study: 39055379
Drug: Intense Pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense Pulsed Light (IPL) therapy
Study: 39055495
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of utidelone and capecitabine
Study: 39055663
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral β-blocker therapy
Study: 39055663
Drug: No β-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: No β-blocker therapy (Control)